Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Plasma cell 1NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Liver Diseases 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 6Cyclophosphamide 6X-Rays 5Phantoms, Imaging 5Filgrastim 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Gemcitabine 4Biopsy 4tazemetostat 3Surveys and Questionnaires 3Psychiatric Rehabilitation 3Etoposide 3Drug Therapy 3Carboplatin 3Busulfan 3Bevacizumab 3ulixertinib 2tipifarnib 2spartalizumab 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ganitumab 2ensartinib 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × repotrectinib × Lymphoid × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡